ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
$2.70M
Mr. Stephen C. Glover
6.00
Weston, FL
Feb 11, 2022
0.00
$1,232.39
0.02
0.11
0.00%
-0.02
0.07
0.00
0.02
-283.19%
-176.45%
Similar stocks (7)
Immix Biopharma, Inc.
IMMX
AVROBIO, Inc.
AVRO
Virios Therapeutics, Inc.
VIRI
CNS Pharmaceuticals, Inc.
CNSP
Hepion Pharmaceuticals, Inc.
HEPA
eFFECTOR Therapeutics, Inc.
EFTR
Navidea Biopharmaceuticals, Inc.
NAVB
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (7)
Immix Biopharma, Inc.
IMMX
AVROBIO, Inc.
AVRO
Virios Therapeutics, Inc.
VIRI
CNS Pharmaceuticals, Inc.
CNSP
Hepion Pharmaceuticals, Inc.
HEPA
eFFECTOR Therapeutics, Inc.
EFTR
Navidea Biopharmaceuticals, Inc.
NAVB
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%